Research Trials
If you have any questions or are interested in participating in one of our clinical trials, please jot down the trial number and contact your Nebraska Cancer Specialists medical oncologist or a member of our clinical research team at 402.334.4773, or email us at clinicaltrials@nebraskacancer.com.
Download All Current Trials
-
Cancer Type:
-
Biomarker:
-
Phase:
-
Keyword:
-
AVM0703-001
An Open-Label, Phase 1/2 Study Evaluating AVM0703 in Patients with Lymphoid MalignanciesCancer Type: Heme
Phase: 1, 2
View Details on ClinicalTrials.gov
-
JZP712-201 (EMERGE-201)
A phase 2, multicenter, open-label study of lurbinectedin efficacy and safety in participants with advanced or metastatic solid tumorsCancer Type: Advanced Solid Tumors
Phase: 2
View Details on ClinicalTrials.gov
-
GS-US-548-5918
A Phase 2, Multi-Arm Study of Magrolimab in Patients with Solid TumorsCancer Type: SOLID: mNSCLC; mSCLC, mUC
Lines of Therapy: 3, 2
Phase: 2
View Details on ClinicalTrials.gov
-
SLSG18-301
A Randomized, Open-Label Study of the Efficacy and Safety of Galinpepimut-S (GPS) Maintenance Monotherapy Compared to Investigator's Choice of Best Available Therapy in Subjects with Acute Myeloid Leukemia Who Have Achieved Complete Remission After Second-Line, or later Salvage TherapyCancer Type: AML
Lines of Therapy: 3
Phase: 3
View Details on ClinicalTrials.gov
-
D-US-60010-001
An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreasCancer Type: Pancreatic
Lines of Therapy: 1
Phase: 3
View Details on ClinicalTrials.gov
-
7465-CL-202
An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202)Cancer Type: Esophageal squamous cell carcinoma (ESCC)
Lines of Therapy: 2
Phase: 2
View Details on ClinicalTrials.gov
-
CO42865 AcceleRET-MTC
A PHASE III, RANDOMIZED, OPEN-LABEL STUDY OF PRALSETINIB VERSUS STANDARD OF CARE FOR TREATMENT OF RET-MUTATED MEDULLARY THYROID CANCERCancer Type: MTC: Medullary Thyroid Cancer
Biomarkers: RET
Phase: 3
View Details on ClinicalTrials.gov
-
C2321001
A Phase 1 Dose Escalation and Expanded Cohort Study Of PF-06821497 In The Treatment Of Adult Patients With Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) And Follicular Lymphoma (FL).Cancer Type: Relapsed/Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC), Follicular Lymphoma (FL)
Phase: 1
View Details on ClinicalTrials.gov
-
AMG 510 (20190436)
A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C MutationCancer Type: Non-small cell lung cancer (NSCLC)
Biomarkers: KRAS p. G12C
Phase: 3b
View Details on ClinicalTrials.gov
-
213400 / ZEAL-1L
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Comparing Niraparib Plus Pembrolizumab Versus Placebo Plus Pembrolizumab as Maintenance Therapy in Participants Whose Disease Has Remained Stable or Responded to First-Line Platinum-Based Chemotherapy with Pembrolizumab for Stage IIIB/IIIC or IV Non-Small Cell Lung CancerCancer Type: NSCLC
Lines of Therapy: 1
Phase: 3
View Details on ClinicalTrials.gov